Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Excerpt from AXON's Aug 15 PR... it touts its combo technology with donepezil to advance the SoC by reducing the adverse side effects of donepezil. This is no solution for Alz; it's just trying to make donepezil less bad. (i.e. lipstick on pig)
"Axovant and Qaam Pharmaceuticals (Qaam) have entered into an exclusive license agreement under which Axovant expects to develop and, if successful, commercialize products that combine cholinesterase inhibitors with peripheral muscarinic receptor antagonists including glycopyrrolate, which could mitigate the peripheral side effects of cholinesterase inhibitors. Axovant will initially develop RVT-103, a combination of glycopyrrolate and donepezil. In addition, Axovant expects to develop RVT-104, a combination of glycopyrrolate and high-dose rivastigmine. Axovant believes that the intellectual property portfolio licensed from Qaam as part of this transaction provides a strong exclusivity position in this area."
"This program continues to build on our efforts to deliver comprehensive solutions to patients diagnosed with dementia," said Axovant Chief Development Officer Dr. Lawrence Friedhoff, who led the development of Aricept (donepezil) for the treatment of Alzheimer's disease through its approval in 1996. "We believe this product candidate can limit the peripheral side effects of cholinesterase inhibitors which frequently represent an obstacle for patients to adopt or remain on therapy."
Someone should author a hit piece on AXON revealing the truth about its flawed approach on an ineffective SOC, and post it on MF and SA. Seriously! Would like to see the responses from AF, JF, CR and the rest of the cabal who support this lame company.
It will not take that long to get patients for a small trial for a disease that affects children. Parents will be eager and willing, knowing the drug is safe. They might have already started to identify potential patients.
Approval for Rett's may very well be the fastest way 2-73 gets approved. If the trial starts in Sept, approval could realistically come in Q1 2017.
PK stands for pharmacokinetic analysis. It's an analysis of how the body processes the drug: distribution, metabolism and excretion. PD (pharmacodynamics) is the corresponding analysis of how the drug affects the body, dosage response and biometrically how well it is hitting its target, etc.
That's like saying, why buy insurance if you're not planning to use it?.
I do not believe there was any proof of AVXL paying for any "pump" promotions. The Argos pump piece was certainly not of AVXL's doing. I firmly believe it was paid by the cabal who were behind pumping up the price in preparation of their planned short attack.
Yes, you're correct; "attack" is the wrong word; should have used "target" instead. Thanks!
Correct... Attacking beta-amyloid, instead of the cause, is analogous to a leaky boat. Bailing out the water will not fix the problem! No matter how advanced your bucket or techniques are.
I doubt they'll use the LPC funds, but if they do, I would suspect they would either be buying time to negotiate more favorable partnership terms...or possibly decide to go it alone (utilizing a drug mfr/distributor instead).
IF they do tap into the LPC funds, I would imagine they would time the transaction after some very good news in order to execute at a more optimal stock price.
I would suspect that those patients were not MCI, but rather mild-to-moderate Alz patients for the simple fact that they had given up their hobbies for a period of time (perhaps years). I doubt an MCI patient would be so afflicted to give up on a hobbie. IMO, of course.
I don't believe you fully understand the purpose of an adaptive open-label trial, which was approved by the FDA. It met its endpoints and the data will enable the company to design a meaningful Phase 3 with a high probability of success.
There is more to this drug (MoA) than just Alzheimer's. Great things are about to happen, including a partner and/or grant.
Yep, and notice that the 5-day money-flow indicator has risen through all of this manipulation...a very unnatural correlation. Appears the conniving crooks are positioning themselves (and their cronies) for the next leg up on the next bit of news.
What do you believe the next catalyst will be and approx. when?
Just as happened last week, the 5-day money-flow indicator (MFI) is rising while the price is being manipulated down. This tells me there is more controlled accumulation going on...and/or short covering.
Certainly seems very likely...
You'll have to provide links, because I don't recall seeing any "pumping" articles. I've seen several positive articles this year based on the science and factual data, but nothing that I would consider "pumping".
If you'll recall, the SP rise prior to AAIC happened with no news. I believe the cabal was behind that rise (then shorting 4M+ shares) in order to set up the coordinated selloff.
Surely you don't believe that these hit pieces are genuine points of view. If so, I've got beach-front property in Montana I'd like to sell you. :)
They are completely fabricated for the purpose of trashing the company, scaring retail and driving the price down. Surely you know this.
Appears to be more accumulation (MFI) under a depressed price.
Those articles are designed purely as cover for daily short trading and trying to scare shares loose. I can't imagine any smart investor, who bought on Friday on good news, would turn around and sell on this garbage.
Well done! It was rather obvious what was happening last week (i.e. accumulation), with the SP being held around $3.00 and the 5-day MFI rising.
From here on out, news and PRs will come at random and the cabal won't be able to anticipate or prepare. Makes for a very dangerous short game.
And I feel sorry for those with red dollars, who have sold. Those that continue to hold, will be very green in due time.
Maybe, maybe not.
And someone is thanking you for your shares...
Don't kid yourself. The cabal had just as much to do with the rising share price into the 2nd of Nov, as they did with the crash the following day, 3 days BEFORE the conference presentation. I've been here since April 2015; I've experienced it all.
Good for you! I got in at $1.08 (eff. post-split). :)
There's certainly some "funny business" going on this week: MFI is rising while the SP is being tightly controlled around $3.00 and not going lower. It would seem that accumulation is happening in preparation for the next leg up.
Going forward, PRs will come unexpectedly, and the cabal cannot anticipate or prepare.
Agreed. I, personally, don't see it as bad, but not sure how the "market" will initially respond to it. To me, it would indicate that they are going it alone (utilizing a drug mfr/distributor) and not BP.
That's why I hope they announce P3 along with grant or partnership news; otherwise, the market will assume straight dilution.
Potential near-term PRs:
- PK/PD data confirming that the drug is working and safe
- Rett's trial announcement
- Parkinson's data release and planned trial
- Alz P2b/3 + Grant and/or Partnership announcement
And these will ALL BE SURPRISE ANNOUNCEMENTS!
It's encouraging to see the 5-day money-flow indicator moving upward...
That's certainly good to see, even though many of those shares are for their biotech index funds.
MMs and hedgies should know by now that they can't shake shares from longs down at this level. If we won't sell at $7, we sure as hell ain't selling at $3. If they want more shares they should be moving this upward in hopes that a large holder will bail at breakeven.
Ha ha! I always look at the technical indicators; they are valuable in identifying overbought and oversold conditions.
Fundamentals? There are no Fundamentals: no revenue, no EPS, etc. What I believe you're referring to, are the science and clinical data... which are the reasons I remain fully loaded.
Looking at past trends, seems we might languish here for another week or so, in lieu of any news. This will allow the MACD to roll under and the Stochastic to bottom out. Just sayin...
To reiterate Xena's response... the data, especially the monotherapy data, indicated a potential curative effect at 31 wks, but is inconclusive only because of the small 'n'. As expressed in Anavex's PR...
"The study also offered encouraging evidence confirming the previously reported positive trends in some cognitive and biologic measures persisted over a period of approximately 31 weeks.
However, the company clarified that this analysis was based on a relatively small number of subjects receiving a variety of doses. Therefore, the company said that that these findings might not reflect the full potential of ANAVEX 2-73 in treating Alzheimer's disease."
AF and the shorting cabal are responsible for the rapid share price decline. They had a premeditated plan to attack, regardless of what the data showed.
My bag is rather nice and will be even nicer as the company progresses its trials on various indications. I'm up only 3x currently... expect a 10 bagger from here in 6-12 months. Yeah, it's in the BAG!
It IS... until it isn't. Time will tell, but my money's on IS!
Here we go again...
The market's view changed with the Part B results
Are you implying that AF's articles represent the feelings of the "market" and his reference to Anavex's trial as being "garbage" accurate?
As you can see, the market called BS on the company claims and is focusing on the longer term interim results as a "show me". Rightly so.
He's baaaack!